Orionis Biosciences announces a $2B+ collaboration with Genentech to develop innovative small-molecule therapies for oncology ...

The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Orionis to receive $105 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovale ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Columvi combo for relapsed diffuse large B-cell lymphoma faces approval hurdle. Discover implications for U.S. Read more here ...

As the summer travel season fast approaches, airlines and airports are ramping up their activities. See who's making changes, ...

The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...

The biotech giant's new facility is part of a larger U.S. investment strategy, though it may roll back its buildout if the ...

Biotech, one of the Bay Area's most important industries, sprang up in five short decades. Here are the key moments to know ...